GHRH Analog Drug Development
The GHRH analog tesamorelin (trade name Egrifta) is a drug for the treatment of lipodystrophy in HIV patients under highly active antiretroviral therapy, approved by the U.S. Food and Drug Administration in November 2010. Chemically it is (3E)-hex-3-enoyl-GHRH. It may also reduce cognitive decline in older humans.
See also earlier work on Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys. CJC-1295, CJC-1293 and Sermorelin.
Read more about this topic: Growth-hormone-releasing Hormone
Famous quotes containing the words drug and/or development:
“If an addict who has been completely cured starts smoking again he no longer experiences the discomfort of his first addiction. There exists, therefore, outside alkaloids and habit, a sense for opium, an intangible habit which lives on, despite the recasting of the organism.... The dead drug leaves a ghost behind. At certain hours it haunts the house.”
—Jean Cocteau (1889–1963)
“Somehow we have been taught to believe that the experiences of girls and women are not important in the study and understanding of human behavior. If we know men, then we know all of humankind. These prevalent cultural attitudes totally deny the uniqueness of the female experience, limiting the development of girls and women and depriving a needy world of the gifts, talents, and resources our daughters have to offer.”
—Jeanne Elium (20th century)